Akebia Therapeutics to Participate in Upcoming Investor Conferences

November 16, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 16, 2017-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in the following investor conferences:

- The 29th Annual Piper Jaffray Healthcare Conference onWednesday, November 29, 2017, at 12:30 p.m. Eastern Time, to be held at the Lotte New York Palace in New York, NY.
- The Evercore ISI Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017, at 9:30 a.m. Eastern Time, to be held at the Boston Harbor Hotel in Boston, MA.
- The Global Mizuho Investor Conference on Tuesday, December 5, 2017, to be held at the Lotte New York Palace in New York, NY.

A live audio webcast from the presentation at Piper Jaffray and fireside chat at Evercore will be available on the Company's website at http://ir.akebia.com/events.cfm, with archives available for 90 days.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral, investigational therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO_2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the $INNO_2VATE$ studies for dialysis-dependent patients, is currently ongoing. In addition, the Company has initiated the Phase 2 FO_2RWARD study of vadadustat in dialysis-dependent chronic kidney disease patients who are hyporesponsive to erythropoiesis-stimulating agents (ESAs), and expects to commence the Phase 3 $TRILO_2GY$ study to further evaluate a three-times-weekly dosing regimen for vadadustat. For more information, please visit our website at www.akebia.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171116005326/en/

Source: Akebia Therapeutics, Inc.

Akebia Therapeutics
John Garabo, 617-844-6130
Director, Corporate Communications
jgarabo@akebia.com